Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis
September 06, 2022 09:00 ET
|
Attralus, Inc
Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition elementThis novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for...
Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis
September 06, 2022 07:00 ET
|
Attralus, Inc
AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleenAT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrilsAT-02 binds potently to multiple types of amyloid...
Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis
August 22, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis
August 08, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
June 14, 2022 11:45 ET
|
Attralus, Inc
AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosisAT-01 visualizes and quantifies organ-specific changes in amyloid load over time AT-01 detected...
Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
June 03, 2022 08:00 ET
|
Attralus, Inc
Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis...
Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
April 04, 2022 08:00 ET
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloidSensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in ALCardiac...
Attralus Appoints James Testa as Vice President of Finance
February 10, 2022 08:00 ET
|
Attralus, Inc
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
December 13, 2021 08:00 ET
|
Attralus, Inc
AT-03 potently binds human AL and ATTR fibrils and is capable of binding diverse forms of systemic amyloid deposits in mouse models AT-03 enhances macrophage-mediated phagocytosis of AL amyloid...
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...